Browse by author
Lookup NU author(s): Dr Nicola Hannaway,
Dr Alastair GreystokeORCiD
This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).
© 2020Lung cancer is the leading cause of cancer mortality worldwide and most patients are unsuitable for ‘gold standard’ treatment, which is concurrent chemoradiotherapy. CONCORDE is a platform study seeking to establish the toxicity profiles of multiple novel radiosensitisers targeting DNA repair proteins in patients treated with sequential chemoradiotherapy. Time-to-event continual reassessment will facilitate efficient dose-finding.
Author(s): Walls GM, Oughton JB, Chalmers AJ, Brown S, Collinson F, Forster MD, Franks KN, Gilbert A, Hanna GG, Hannaway N, Harrow S, Haswell T, Hiley CT, Hinsley S, Krebs M, Murden G, Phillip R, Ryan AJ, Salem A, Sebag-Montefoire D, Shaw P, Twelves CJ, Walker K, Young RJ, Faivre-Finn C, Greystoke A
Publication type: Article
Publication status: Published
Journal: Clinical and Translational Radiation Oncology
Print publication date: 01/11/2020
Online publication date: 21/09/2020
Acceptance date: 15/09/2020
Date deposited: 14/01/2021
ISSN (electronic): 2405-6308
Publisher: Elsevier Ireland Ltd
Altmetrics provided by Altmetric